SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy

Experts provide their thoughts on key data in breast and gynecologic cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: August 17, 2022 Expired: August 16, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director Thomas Stinchcombe, MD
Program Director Released: August 4, 2022

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director Released: August 4, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022